[Skip to Navigation]
March 12, 2020

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor

Author Affiliations
  • 1Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
  • 2Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. 2020;138(4):418-419. doi:10.1001/jamaophthalmol.2020.0110

Acute myeloid leukemia (AML) is a malignant condition of poorly differentiated hematopoietic progenitor cells.1 The disease can manifest in the eye with tissue hemorrhage or infiltration and be the presenting sign of systemic disease or evidence of relapse. Most frequently, leukemic infiltration involves the retina or choroid, whereas iridociliary involvement is rare.2,3 Management of the systemic disease is key to controlling leukemic ophthalmopathy, but often the eye requires additional radiotherapy, especially for optic-nerve involvement.3

Add or change institution